# Bias Audit Plan for Aarogya Sahayak

## Overview

This document outlines the planned approach for assessing and mitigating bias in the Aarogya Sahayak clinical decision support system. Bias auditing is essential to ensure equitable healthcare AI that serves diverse patient populations without discrimination.

---

## Demographic Bias Assessment

### Objectives

Evaluate whether the system provides equitable performance across different demographic groups, including:

- **Age Groups**: Pediatric, adult, geriatric populations
- **Gender**: Male, female, non-binary patients
- **Geographic Location**: Urban vs. rural settings, different Indian states
- **Socioeconomic Status**: Different income levels and insurance coverage
- **Comorbidity Burden**: Patients with single vs. multiple chronic conditions

### Planned Methodology

#### 1. Data Collection

- **Stratified Sampling**: Collect clinical notes representing diverse demographics
- **Minimum Sample Size**: 100 notes per demographic subgroup
- **Balanced Representation**: Ensure proportional representation matching Indian population demographics
- **Metadata Tracking**: Record demographic attributes (de-identified) for each test case

#### 2. Performance Metrics by Subgroup

Measure the following metrics across each demographic group:

- **Confidence Score Distribution**: Compare mean and variance of confidence scores
- **Hallucination Alert Rate**: Frequency of poorly grounded recommendations
- **Evidence Quality**: Average cosine similarity of retrieved evidence
- **Clinician Review Flag Rate**: Proportion of actions requiring review
- **Processing Time**: Latency differences across groups

#### 3. Disparity Analysis

- **Statistical Testing**: Chi-square tests for categorical outcomes, t-tests for continuous metrics
- **Disparity Thresholds**: Flag disparities \u003e10% between any two groups
- **Intersectionality**: Analyze combined effects (e.g., elderly + rural + female)

#### 4. Root Cause Investigation

For identified disparities:

- **Evidence Corpus Analysis**: Check if corpus underrepresents certain conditions
- **Language Patterns**: Assess if clinical note phrasing affects certain groups
- **Model Behavior**: Investigate if LLM exhibits demographic-specific biases

### Planned Interventions

- **Corpus Augmentation**: Add literature covering underrepresented conditions
- **Prompt Engineering**: Adjust prompts to reduce demographic-specific biases
- **Confidence Calibration**: Adjust confidence thresholds per demographic if needed
- **Clinician Feedback**: Incorporate expert review of flagged disparities

### Success Criteria

- **No Significant Disparities**: \u003c5% difference in key metrics across demographics
- **Transparent Reporting**: Publish bias audit results in documentation
- **Continuous Monitoring**: Establish ongoing bias monitoring in production

---

## Language Bias Evaluation

### Objectives

Assess whether multilingual patient summaries provide equivalent quality and comprehensibility across Hindi and Tamil, and identify any language-specific biases.

### Planned Methodology

#### 1. Translation Quality Assessment

- **Back-Translation**: Translate Hindi/Tamil summaries back to English, compare to original
- **Bilingual Expert Review**: Medical professionals fluent in both languages review summaries
- **Terminology Accuracy**: Verify medical terms are correctly translated
- **Cultural Appropriateness**: Assess if translations respect cultural health beliefs

#### 2. Readability Evaluation

- **Reading Level**: Validate 6th-grade reading level using language-specific tools
- **Sentence Length**: Measure average sentence length (target ≤15 words)
- **Comprehension Testing**: Test with native speakers of varying literacy levels
- **Jargon Frequency**: Count untranslated medical jargon per summary

#### 3. Comparative Analysis

Compare Hindi vs. Tamil summaries on:

- **Information Completeness**: Ensure no information loss in translation
- **Clarity**: Subjective ratings from bilingual reviewers
- **Actionability**: Can patients understand and act on recommendations?
- **Consistency**: Same clinical note should produce equivalent summaries

#### 4. Language-Specific Challenges

Identify challenges unique to each language:

- **Hindi**: Devanagari script readability, Sanskrit-derived medical terms
- **Tamil**: Agglutinative grammar, Dravidian language structure differences
- **Code-Switching**: Assess if mixing English medical terms is acceptable

### Planned Interventions

- **Professional Translation**: Replace mock translations with validated medical translations
- **Glossary Development**: Create Hindi/Tamil medical terminology glossaries
- **User Testing**: Pilot with actual patients in Hindi/Tamil-speaking regions
- **Iterative Refinement**: Update translation prompts based on feedback

### Success Criteria

- **Equivalent Quality**: \u003c10% difference in comprehension scores between languages
- **High Readability**: \u003e80% of target population can understand summaries
- **Cultural Acceptance**: Positive feedback from community health workers
- **No Information Loss**: 100% of critical information preserved in translation

---

## Evidence Source Diversity Analysis

### Objectives

Evaluate whether the evidence corpus represents diverse medical perspectives, geographic contexts, and patient populations, ensuring recommendations are globally informed and locally relevant.

### Planned Methodology

#### 1. Corpus Composition Analysis

Analyze the PMC Open Access corpus on:

- **Geographic Origin**: Distribution of studies by country/region
- **Publication Dates**: Recency of evidence (prioritize last 5 years)
- **Study Types**: RCTs, meta-analyses, observational studies, case reports
- **Patient Demographics**: Populations studied (age, ethnicity, comorbidities)
- **Disease Coverage**: Breadth of conditions represented

#### 2. Indian Context Representation

Assess relevance to Indian healthcare:

- **India-Specific Studies**: Proportion of studies conducted in India
- **Resource-Constrained Settings**: Evidence from low-resource contexts
- **Tropical Diseases**: Coverage of conditions prevalent in India (e.g., dengue, TB)
- **Dietary Patterns**: Nutrition studies relevant to Indian diets
- **Traditional Medicine**: Integration of Ayurveda/traditional practices

#### 3. Retrieval Bias Analysis

Evaluate if retrieval favors certain types of evidence:

- **Citation Bias**: Do highly cited papers dominate results?
- **Recency Bias**: Are newer studies over-represented?
- **Language Bias**: Are non-English studies underrepresented?
- **Journal Prestige Bias**: Do top-tier journals dominate?

#### 4. Recommendation Diversity

Analyze action items generated:

- **Treatment Diversity**: Range of medication classes recommended
- **Lifestyle Interventions**: Balance of pharmacological vs. non-pharmacological
- **Specialist Referrals**: Diversity of specialties recommended
- **Preventive vs. Curative**: Balance of prevention and treatment actions

### Planned Interventions

- **Corpus Expansion**: Prioritize adding Indian and South Asian studies
- **Diversity Weighting**: Adjust retrieval to balance geographic/demographic diversity
- **Local Guidelines**: Incorporate Indian clinical practice guidelines (ICMR, NCD guidelines)
- **Community Input**: Engage Indian clinicians in corpus curation

### Success Criteria

- **Geographic Balance**: ≥30% of evidence from low- and middle-income countries
- **Indian Representation**: ≥20% of evidence from Indian studies or relevant to Indian context
- **Temporal Recency**: ≥70% of evidence from last 10 years
- **Study Type Diversity**: Representation across RCTs, systematic reviews, cohort studies
- **Demographic Diversity**: Evidence covers diverse age, gender, and comorbidity profiles

---

## Audit Timeline and Responsibilities

### Phase 1: Planning (Months 1-2)

- **Deliverable**: Finalize audit methodology and metrics
- **Responsible**: AI Ethics Team + Clinical Advisory Board
- **Milestone**: Approved audit protocol

### Phase 2: Data Collection (Months 3-4)

- **Deliverable**: Stratified dataset of 1,000+ clinical notes with demographics
- **Responsible**: Data Engineering Team + Clinical Partners
- **Milestone**: Validated, de-identified dataset

### Phase 3: Bias Testing (Months 5-6)

- **Deliverable**: Quantitative bias metrics across all dimensions
- **Responsible**: ML Engineering Team + Biostatisticians
- **Milestone**: Bias audit report with statistical analysis

### Phase 4: Intervention Design (Month 7)

- **Deliverable**: Mitigation strategies for identified biases
- **Responsible**: Cross-functional team (ML, Clinical, Ethics)
- **Milestone**: Approved intervention plan

### Phase 5: Implementation (Months 8-9)

- **Deliverable**: Updated system with bias mitigations
- **Responsible**: Engineering Team
- **Milestone**: Deployed bias-mitigated system

### Phase 6: Re-Audit (Month 10)

- **Deliverable**: Post-intervention bias assessment
- **Responsible**: Independent Auditors
- **Milestone**: Verified bias reduction

### Phase 7: Continuous Monitoring (Ongoing)

- **Deliverable**: Quarterly bias monitoring reports
- **Responsible**: AI Governance Team
- **Milestone**: Sustained equitable performance

---

## Reporting and Transparency

### Internal Reporting

- **Monthly Updates**: Progress reports to leadership and clinical advisory board
- **Incident Reporting**: Immediate escalation of severe bias incidents
- **Stakeholder Briefings**: Regular updates to clinicians, patients, and ethicists

### External Transparency

- **Public Bias Report**: Annual publication of bias audit findings
- **Model Card**: Detailed documentation of model limitations and bias considerations
- **Academic Publication**: Peer-reviewed paper on bias mitigation approaches
- **Community Engagement**: Town halls with patient advocacy groups

### Accountability Mechanisms

- **Ethics Review Board**: Independent oversight of bias audit process
- **Patient Representatives**: Include patient voices in audit design
- **Regulatory Compliance**: Align with emerging AI fairness regulations
- **Third-Party Audits**: Periodic independent bias assessments

---

## Limitations of Current Plan

### Resource Constraints

- **Sample Size**: May be underpowered for rare demographic subgroups
- **Geographic Coverage**: Limited to select Indian states initially
- **Language Scope**: Only Hindi and Tamil (excludes 20+ other Indian languages)

### Methodological Challenges

- **Confounding**: Difficult to isolate bias from legitimate clinical differences
- **Ground Truth**: No gold standard for "correct" clinical recommendations
- **Intersectionality**: Combinatorial explosion of demographic intersections
- **Dynamic Bias**: Bias may evolve as model and corpus are updated

### Ethical Considerations

- **Privacy**: Demographic data collection risks re-identification
- **Stigma**: Highlighting disparities may stigmatize certain groups
- **Intervention Trade-offs**: Reducing bias for one group may affect another

---

## Future Enhancements

1. **Algorithmic Fairness Metrics**: Implement demographic parity, equalized odds
2. **Causal Bias Analysis**: Use causal inference to identify bias mechanisms
3. **Participatory Design**: Co-design bias audits with affected communities
4. **Real-World Monitoring**: Track bias in actual clinical deployments
5. **International Collaboration**: Align with global AI fairness initiatives (WHO, IEEE)

---

**Status**: Placeholder Document (Not Yet Implemented)  
**Next Steps**: Secure funding and partnerships for comprehensive bias audit  
**Contact**: [Research Team Email]

**Last Updated**: February 2026  
**Version**: 0.1.0 (Planning Phase)
